Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports
Sleep Medicine · 2027-01 · 149 · 109264
DOI: 10.1016/j.sleep.2026.109264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep Medicine, 2027-01. Verfasst von Abanoub J Armanious und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, 08854, USA; Brain Health Institute, Rutgers Biomedi…. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Sydney, National Institute on Drug Abuse, National Health and Medical Research Council.
Abstract (Originalsprache)
BACKGROUND: Lemborexant is a dual orexin receptor antagonist (DORA) approved for the clinical management of insomnia. Clinical trials indicate that lemborexant improves sleep onset latency and sleep maintenance, with mild somnolence as the most common side effect. However, there is limited real-world evidence characterizing patient experiences with lemborexant, including perceived benefits, side effects, and overall treatment satisfaction, and how these factors influence treatment adherence and discontinuation. METHODS: We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant. A total of 260 online reviews were subjected to reflexive thematic analysis to identify themes relating to user-reported benefits, adverse effects, and broader treatment-related experiences. We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment. RESULTS: Approximately one third (30%) of respondents described meaningful improvements in sleep quality following initiation with lemborexant; half (50%) reported minimal or no perceived benefit. Two-thirds (68%) of respondents reported at least one adverse outcome associated with treatment; the most frequently reported were exacerbated oneiric experiences (e.g., vivid dreams or nightmares) and worsening of sleep quality. Lower efficacy ratings and discontinuation intent were most strongly associated with self-reported sleep paralysis, intensified oneiric phenomena, and next-day somnolence. Longer treatment duration was associated with higher perceived efficacy ratings. CONCLUSIONS: Patient-reported experiences with lemborexant reveal marked variability in perceived benefit and tolerability. Dream-related phenomena emerged as particularly salient themes in shaping respondents' overall perceptions of lemborexant and intent to continue vs. discontinue treatment. Together, these findings highlight the value of real-world infoveillance approaches for capturing patient-centered treatment experiences that may be underrepresented in structured clinical trial and postmarketing surveillance data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, 08854, USA; Brain Health Institute, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, 08854, USA.
- Division of Addictions, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23284, USA; Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, 23284, USA.
- Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, 08854, USA; Brain Health Institute, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, 08854, USA; S…
Förderung
- The University of Sydney
- National Institute on Drug Abuse
- National Health and Medical Research Council
Zitieren
APA
Armanious, A. J., Dunn, A. R., Martin, C. E., & James, M. H. (2027). Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports. Sleep Medicine, 149, 109264. https://doi.org/10.1016/j.sleep.2026.109264
Vancouver
Armanious AJ, Dunn AR, Martin CE, James MH. Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports. Sleep Medicine. 2027;149:109264. doi:10.1016/j.sleep.2026.109264
BibTeX
@article{Armanious2027,
author = {Armanious, Abanoub J and Dunn, Alexandra R and Martin, Caitlin E and James, Morgan H},
title = {Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports},
journal = {Sleep Medicine},
year = {2027},
volume = {149},
pages = {109264},
doi = {10.1016/j.sleep.2026.109264}
}
EUVIMED